U.S. Weight Loss Market Now Worth $135 Billion, as Medical Programs Fuel Growth

The value of the total market is estimated to have grown to a historic peak of $135 billion in 2025, boosted by soaring sales of the popular prescription GLP-1 weight loss drugs. This is a paradigm shift to medical...

Mar 22, 2026 - 19:37

0 12

U.S. Weight Loss Market Now Worth $135 Billion, as Medical Programs Fuel Growth

Happy woman holding a weight scale at the gym-1 The value of the total market is estimated to have grown to a historic peak of $135 billion in 2025, boosted by soaring sales of the popular prescription GLP-1 weight loss drugs. This is a paradigm shift to medical programs, and a major challenge for competing commercial weight loss companies.

GLP-1 drugs are a game changer in terms of the number of medications now on the market, plus others to come in the next several years. They have affected dieter behavior and how commercial diet companies operate. Nearly all non-medical segments of the market have felt the pain of declining sales, and 26,000+ weight loss coaches have lost their jobs. However, more physicians are adding weight loss to their practices, the number of bariatricians is hitting new highs, and the number of franchised/chain medical weight loss centers has grown.

Top things to know about this market:

Market Size… The total U.S. weight loss market was worth $135 billion in 2025 (when including the revenues of health clubs). A 6.6% increase is forecast in 2026, largely due to growing sales of GLP-1 drugs. Commercial weight loss companies/centers (Weight Watchers, NutriSystem, jenny Craig, Medifast) saw revenues fall by 24% as a group in 2025, to $1.86 billion, as they struggle to pivot and deal with strong competition from the GLP-1 drugs. Medical programs (including drugs) accounted for a new high of 38% of the total market value, worth $51.5 billion last year. This is up sharply from 11% in 2022, prior to the GLP-1 drugs boom. Bariatric surgery volume is estimated to have fallen by 8% in 2024 and another 6% in 2025, to 232,000. The market for prescription obesity medications (GLP-1s) is estimated to have increased by 64% in 2025, to $43.48 billion. Growth will be slower in 2026, as new and cheaper oral weight loss pills enter the market. Meal replacements and retail appetite suppressants is a $4.2 billion market. Shakes and nutrition bars have held up well but retail diet pills sales are plummeting.

To learn more about this market, purchase the full report: The U.S. Weight Loss Market: 2026 Status Report & Forecast